Spark begins Phase I/II trial of SPK-CHM to treat Choroideremia
The open-label, dose-escalating Phase I/II trial is designed to evaluate the safety and preliminary efficacy of sub-retinal administration of SPK-CHM. Spark co-founder and chief executive officer Jeffrey Marrazzo